Xembify
Sponsors
Grifols Therapeutics LLC
Conditions
B-cell Chronic Lymphocytic LeukemiaBacterial InfectionsCIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)HypogammaglobulinemiaMultiple MyleomaNon-Hodgkin Lymphoma
Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RecruitingNCT05645107
Start: 2022-12-26End: 2029-08-01Target: 386Updated: 2026-07-29
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
RecruitingNCT07540221
Start: 2026-04-02End: 2027-12-31Target: 40Updated: 2026-09-04